The U.S. Food and Drug Administration (FDA) has approved a wearable medical device used in combination with a standard chemotherapy regimen for the treatment of adult patients with locally advanced ...
USA: Researchers have drawn attention to an unusual but potentially distressing adverse effect linked to a commonly used postoperative treatment for non–muscle-invasive bladder cancer (NMIBC). A multi ...
FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...
FDA approved Optune Pax for locally advanced pancreatic cancer with gemcitabine/nab-paclitaxel, marking the first new modality in decades for this nonresectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results